Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
FDA Orange Book
0
Europe
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Cloprostenol
2. Cloprostenol Monosodium Salt
3. Estrumate
4. Ici 80,966
5. Ici-80,966
6. Ici80,966
7. Monosodium Salt, Cloprostenol
8. Oestrophan
9. Salt, Cloprostenol Monosodium
10. Sodium, Cloprostenol
1. 62561-03-9
2. 55028-72-3
3. (+)-cloprostenol Sodium
4. Estrumate
5. Cloprostenol Sodium Salt
6. D-cloprostenol Sodium Salt
7. Sodium (z)-7-((1r,2r,3r,5s)-2-((r,e)-4-(3-chlorophenoxy)-3-hydroxybut-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enoate
8. (+)-cloprostenol (sodium Salt)
9. (+/-)-cloprostenol Sodium Salt
10. Cloprostenol Sodium, (+)-
11. 81129i41bj
12. 886sav9675
13. Ici 80,996
14. Ici 80996
15. Planate
16. Sodium;(z)-7-[(1r,2r,3r,5s)-2-[(e,3r)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate
17. Sodium;(z)-7-[(1s,2s,3s,5r)-2-[(e,3s)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate
18. Estroplan
19. Sodium Cloprostenol
20. 5-heptenoic Acid, 7-((1r,2r,3r,5s)-2-((1e,3r)-4-(3-chlorophenoxy)-3-hydroxy-1-buten-1-yl)-3,5-dihydroxycyclopentyl)-, Sodium Salt (1:1), (5z)-
21. Ncgc00165774-02
22. Cloprostenol Sodium [usan]
23. Unii-886sav9675
24. Cloprostenol Sodium [usan:usp]
25. Einecs 259-439-3
26. Mfcd05863539
27. D-cloprostenol Sodium
28. Dsstox_cid_26500
29. Dsstox_rid_81669
30. Dsstox_gsid_46500
31. Schembl28242
32. Mls000028831
33. Bml2-g09
34. Chembl1520583
35. Dtxsid1046500
36. Unii-81129i41bj
37. Hms1361o21
38. Hms2235o09
39. Hms3268j10
40. Hms3413c18
41. Amy30120
42. Cloprostenol Sodium [mart.]
43. Ex-a1351
44. Tox21_112261
45. Cloprostenol Sodium [usp-rs]
46. Akos015967190
47. Akos024457034
48. Ac-6102
49. Cloprostenol Sodium [green Book]
50. Ncgc00159550-01
51. (+-)-sodium (z)-7-((1r*,2r*,3r*,5s*)-2-((e)-(3r*)-4-(m-chlorophenoxy)-3-hydroxy-1-butenyl)-3,5-dihydroxycyclopentyl)-5-heptenoate
52. Ac-25916
53. Cloprostenol Sodium [usp Impurity]
54. Smr000058871
55. Cloprostenol Sodium [usp Monograph]
56. Cas-55028-72-3
57. (+)-16-m-chlorophenoxy Tetranor Pgf2alpha
58. C75577
59. A850969
60. J-524247
61. J-524252
62. 16-(m-chlorophenoxy)-tetranor- Prostaglandin F2alpha,sodium Salt
63. (+/-)-sodium (z)-7-((1r*,2r*,3r*,5s*)-2-((e)-(3r*)-4-(m-chlorophenoxy)-3-hydroxy-1-butenyl)-3,5-dihydroxycyclopentyl)-5-heptenoate
64. (5z)-rel-7-[(1r,2r,3r,5s)-2-[(1e,3r)-4-(3-chlorophenoxy)-3-hydroxy-1-butenyl]-3,5-dihydroxycyclopentyl]-5-heptenoic Acid Monosodium Salt
65. (z)-7-[2beta-[(1e,3r)-4-(3-chlorophenoxy)-3-hydroxy-1-butenyl]-3alpha,5alpha-dihydroxycyclopentan-1alpha-yl]-5-heptenoic Acid Sodium Salt
66. 5-heptenoic Acid, 7-((1r,2r,3r,5s)-2-((1e,3r)-4-(3-chlorophenoxy)-3-hydroxy-1-butenyl)-3,5-dihydroxycyclopentyl)-, Monosodium Salt, (5z)-rel-
67. 5-heptenoic Acid, 7-((1r,2r,3r,5s)-2-((1e,3s)-4-(3-chlorophenoxy)-3-hydroxy-1-buten-1-y))-3,5-dihydroxycyclopentyl)-, Sodium Salt (1:1),(5z)-rel-
68. 5-heptenoic Acid, 7-(2-(4-(3-chlorophenoxy)-3-hydroxy-1-butenyl)-3,5-dihydroxycyclopentyl)-, (1a(z),2b(1e,3r*),3.alpha.,5.alpha.)-, Sodium Salt, (+/-)-
69. 5-heptenoic Acid, 7-(2-(4-(3-chlorophenoxy)-3-hydroxy-1-butenyl)-3,5-dihydroxycyclopentyl)-, (1alpha(z),2beta(1e,3r*),3alpha,5alpha)-, Sodium Salt, (+-)-
70. 5-heptenoic Acid, 7-(2-(4-(3-chlorophenoxy)-3-hydroxy-1-butenyl)-3,5-dihydroxycyclopentyl)-, Monosodium Salt, (1alpha(z),2beta(1e,3r*),3alpha,5alpha)-(+-)-
71. Sodium (1alpha(z),2beta(1e,3r*),3alpha,5alpha)-(1)-7-(2-(4-(3-chlorophenoxy)-3-hydroxybut-1-enyl)-3,5-dihydroxycyclopentyl)hept-5-enoate
72. Sodium (e)-7-((1r,2r,3r,5s)-2-((r,e)-3-(3-chlorophenoxy)-3-hydroxyprop-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enoate
73. Sodium (z)-rel-7-((1r,2r,3r,5s)-2-((r,e)-4-(3-chlorophenoxy)-3-hydroxybut-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enoate
74. Sodium(z)-7-((1r,2r,3r,5s)-2-((r,e)-4-(3-chlorophenoxy)-3-hydroxybut-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enoate
| Molecular Weight | 446.9 g/mol |
|---|---|
| Molecular Formula | C22H28ClNaO6 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 11 |
| Exact Mass | 446.1472106 g/mol |
| Monoisotopic Mass | 446.1472106 g/mol |
| Topological Polar Surface Area | 110 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 558 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 2 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Luteolytic Agents
Chemical compounds that cause LUTEOLYSIS or degeneration of the CORPUS LUTEUM. (See all compounds classified as Luteolytic Agents.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Parenteral
Controlled & Modified Release
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Cloprostenol Sodium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cloprostenol Sodium, including repackagers and relabelers. The FDA regulates Cloprostenol Sodium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cloprostenol Sodium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cloprostenol Sodium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cloprostenol Sodium supplier is an individual or a company that provides Cloprostenol Sodium active pharmaceutical ingredient (API) or Cloprostenol Sodium finished formulations upon request. The Cloprostenol Sodium suppliers may include Cloprostenol Sodium API manufacturers, exporters, distributors and traders.
click here to find a list of Cloprostenol Sodium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Cloprostenol Sodium DMF (Drug Master File) is a document detailing the whole manufacturing process of Cloprostenol Sodium active pharmaceutical ingredient (API) in detail. Different forms of Cloprostenol Sodium DMFs exist exist since differing nations have different regulations, such as Cloprostenol Sodium USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cloprostenol Sodium DMF submitted to regulatory agencies in the US is known as a USDMF. Cloprostenol Sodium USDMF includes data on Cloprostenol Sodium's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cloprostenol Sodium USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cloprostenol Sodium suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cloprostenol Sodium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cloprostenol Sodium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cloprostenol Sodium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cloprostenol Sodium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cloprostenol Sodium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cloprostenol Sodium suppliers with NDC on PharmaCompass.
Cloprostenol Sodium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cloprostenol Sodium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cloprostenol Sodium GMP manufacturer or Cloprostenol Sodium GMP API supplier for your needs.
A Cloprostenol Sodium CoA (Certificate of Analysis) is a formal document that attests to Cloprostenol Sodium's compliance with Cloprostenol Sodium specifications and serves as a tool for batch-level quality control.
Cloprostenol Sodium CoA mostly includes findings from lab analyses of a specific batch. For each Cloprostenol Sodium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cloprostenol Sodium may be tested according to a variety of international standards, such as European Pharmacopoeia (Cloprostenol Sodium EP), Cloprostenol Sodium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cloprostenol Sodium USP).
LOOKING FOR A SUPPLIER?
